Nevertheless, it could be beneficial to use KIF11 as an alternative biomarker of oxaliplatin application or in combination therapy of oxaliplatin with a KIF11 inhibitor for CRC patients. This evidence concerns the gene KIF11 and colorectal carcinoma.